Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2005

Matsueda Satoko, Takedatsu Hiroko, Yao Akihisa, Tanaka Masahiro, Noguchi Masanori, Itoh Kyogo, Harada Mamoru

Abstract excerpt

PURPOSE: The peptide vaccine candidates identified to date have been focused on the HLA-A2 and HLA-A24 alleles. The HLA-A11, HLA-A31, and HLA-A33 alleles share binding motifs and belong to an HLA-A3 supertype family. In this study, we attempted to identify CTL-directed peptide candidates, derived from prostate-related antigens and shared by HLA-A11+, HLA-A31+, and HLA-A33+ prostate cancer patients. EXPERIMENTAL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acid Phosphatase
Share to Antigens, Surface

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Epitopes, T-Lymphocyte

Share to HLA-A11 Antigen

Share to HLA-A3 Antigen

Share to Prostate-Specific Antigen

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 16203785
DOI: 10.1158/1078-0432.CCR-05-0682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.PMID 16203785Read ↗

An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.Semantic proximity Read ↗

Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.Semantic proximity Read ↗

Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.Semantic proximity Read ↗

New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.Semantic proximity Read ↗

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.Semantic proximity Read ↗

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.Semantic proximity Read ↗

New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.Semantic proximity Read ↗

Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.Semantic proximity Read ↗

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.Semantic proximity Read ↗

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.Semantic proximity Read ↗

Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients.Semantic proximity Read ↗

Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.